Antibody Drugs: Technologies and Global Markets

Published - Feb 2012| Analyst - Esther Bosklopper| Code - BIO016H
Market Research Report Single User License: $2993

Report Highlights

The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011.  With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.

Report Scope

This report analyzes and assesses therapeutic applications of mAbs in human medicine.  Covered in this report are mAbs exclusively, including the combination of mAbs when they are attached to a cytotoxic agent such as with ADCs.

Excluded from this report are diagnostic uses of mAbs (such as for imaging purposes) and therapeutic antibodies for veterinary use.  Also excluded are research applications of mAbs.

The scope of the study is global.  The “Overview” section provides a discussion of the importance and advantages of antibody-based products, valuation of antibody product sales, patent issues and differences in applicability of mAbs products versus polyclonal antibodies (pAbs), and other competing agents such as small molecule therapeutics.

The “Technology and Technical Issues” section discusses new directions in antibody research, the types of antibodies used as therapeutics, the challenges in antibody production, and other approaches—in particular transgenic sources—of antibody production.

The “Products” section provides a synopsis of more than 60 mAb drugs, including those currently marketed and those in late-stage development.  Comparative product and sales analyses are provided for individual products.  Tables include current and forecasted sales by individual product, sales by target and technology (for mAb-based drugs), as well as global market size and growth estimates for therapeutic mAbs.

The “Applications” section provides an overview of the leading indications for available and emerging antibody-based therapeutics.  These include selected indications for autoimmune diseases (specifically rheumatoid arthritis, psoriasis, and Crohn’s disease), cancer indications (specifically the most common solid tumor types, leukemias, and lymphomas) cardiovascular diseases, infectious diseases, ophthalmic indications, and respiratory diseases.

The “Industry Structure” section provides an overview of  the antibody industry as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.

The “Company Profiles” section emphasizes companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

Analyst Credentials

Esther Bosklopper has been an analyst working in the biotechnology and pharmaceutical industry and other life sciences industries for more than six years.  She holds a degree from the University of California, Davis.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at(+1) 781-489-7301 or contact us at
Title/Chapter Name Pages Price
Full Report: Antibody Drugs: Technologies and Global Markets 193 $2993
Chapter- 1: INTRODUCTION 4
Chapter- 2: SUMMARY 2 $250
Chapter- 3: OVERVIEW 8 $186
Chapter- 5: PRODUCTS 74 $1721
Chapter- 6: APPLICATIONS 24 $558
Chapter- 7: INDUSTRY STRUCTURE 30 $698
List of Tables
List of Figures
Download Table of Contents
Share This Report